Answer
Pralsetinib targets abnormal RET fusion proteins, so a validated test is needed to confirm that the cancer has the alteration the treatment is designed to inhibit.
Sources for this answer
- Gavreto 100 mg hard capsules — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.